MiMedx Group, Inc. (NASDAQ:MDXG) Q1 2022 Earnings Conference Call May 4, 2022 8:30 AM ET

Company Participants

Jack Howarth - Senior Vice President, Investor Relations

Tim Wright - Chief Executive Officer

Pete Carlson - Chief Financial Officer

Rohit Kashyap - Executive Vice President and Chief Commercial Officer

Robert Stein - Executive Vice President, Research and Development

Conference Call Participants

Swayampakula Ramakanth - H.C. Wainwright

Anthony Petrone - Mizuho Group

Carl Byrnes - Northland Capital Markets

John Vandermosten - Zacks SCR

Operator

Ladies and gentlemen, thank you for standing by. And welcome to the MiMedx First Quarter 2022 Operating and Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.

I would now like to turn the conference over to your speaker, Mr. Jack Howarth, Senior Vice President of Investor Relations. Please go ahead, sir.

Jack Howarth

Thank you, operator, and good morning, everyone. Welcome to the MiMedx first quarter 2022 operating and financial results conference call. With me on today's call are Chief Executive Officer, Tim Wright; Chief Financial Officer, Pete Carlson; President Wound Care and Surgical, Dr. Rohit Kashyap and President, Regenerative Medicine and Biologics Innovation, Dr. Robert Stein. Tim and Pete will provide a summary of our operating and financial results for the quarter. And at the conclusion of their remarks, Tim and Pete and Dr. Kashyap and Stein will be available for your questions.

Before we begin, I would like to remind you that our comments today will include forward-looking statements, including potential time lines for our ongoing clinical trials, and FDA submissions and approvals and expected market size for these products. These expectations are subject to risks and uncertainties, and actual results may differ materially from those anticipated due to many factors.

Actual timing and FDA approval will depend on a number of factors, including the results of our clinical trials, our interpretation of those results, the impact of COVID-19, actions by others that affect our time lines and other factors that the FDA deems important. Additional factors that could impact outcomes and our results include those described in the Risk Factors section of our annual report on Form 10-K and our quarterly reports on Form 10-Q.

Also, our comments today include non-GAAP financial measures, as we provide a reconciliation to GAAP in our press release, which is available on our website at www.mimedx.com.